-
Centre Medical Secures Tens of Millions in Series A Financing to Expand Globally
•
Centre Medical, a Hong Kong-based cardiovascular specialized medical services provider, has reportedly raised tens of millions of US dollars in a Series A financing round. Lake Bleu Capital led the investment, with participation from Asia Pacific Medical Group. The funds will be directed towards the company’s globalization strategy, with a…
-
Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations
•
OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of RMB 200 million (USD 27.8 million) in a pre-IPO financing round. The round was led by CCB Private Equity Investment and Huajin Capital, with participation from Guoxin Capital and Befor Capital. The funds will be…
-
Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”
•
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal for a convertible bond issuance, now expecting to raise RMB434 million, a decrease of RMB100 million compared to the initial target of RMB534 million set in November 2022. Proceeds Allocation for Strategic Projects and Working…
-
Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs
•
China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in funding from Beijing E-town International Investment & Development Co., Ltd. The investment is designated to support the research and development of the company’s pipeline programs, including the KRAS G12C-targeted glecirasib and other key projects. Jacobio’s…
-
ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion
•
China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to RMB 160 million (USD 22 million) through a private placement. The net proceeds from this capital increase are designated for Contract Development and Manufacturing Organization (CDMO) work on innovative peptide drugs, the industrialization of active…
-
Henlius Biotech Suspends IPO on STAR Market, Aims to Optimize Capital Strategy
•
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the suspension of its initial public offering (IPO) to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR), prioritizing capital market planning. The company assures that this decision will not affect its daily operations. Henlius initially planned to dual-list on the STAR…
-
Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round
•
Sinotau Pharmaceutical Group, a prominent nuclear medicine (radiopharmaceutical) company headquartered in Beijing, has reportedly raised over RMB 1.1 billion (USD 150 million) in a new financing round. This capital influx is set to bolster the company’s research and development efforts, as well as the clinical application of diagnostic and therapeutic…
-
Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development
•
Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800 million (USD 110 million) in its latest financing round. The investment was led by BridgeOne Capital and Lenovo Capital, with participation from existing investors Tsing Song Capital, Meituan LONG-Z, Qiming Venture Partners, Lilly Asia Ventures,…
-
Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion
•
Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD 152 million) in a Series C financing round. The funding was led by DT Capital, Baron Capital, YSIM Fund, Jiansu Private Equity Fund, Kequan Fund, and a European financial institute. The proceeds will be allocated…
-
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
•
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), has priced its initial public offering (IPO) filing to the Hong Kong Stock Exchange at a range of HKD 60.6 to 72.8 per share. At an assumed offering price of HKD 60.60…
-
BDgene Technology Secures Over RMB 200 Million in Series B Financing Led by Lapam Capital
•
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million (USD 27.7 million) in a Series B financing round. The round was led by Lapam Capital, with additional investments from Penglai Capital, Hermed Capital, Sunland Fund, and Sprinvest. The funds raised will be allocated towards…
-
Aureka Biotechnologies Secures $10 Million in Seed Funding for AI-Driven Biotechnology
•
Aureka Biotechnologies Inc., a California-based artificial intelligence (AI)-empowered biotech company, has successfully raised USD 10 million through a seed financing round led by K2 Venture Partners and Newerli Capital, both China-based private equity funds. The funds will be directed towards the research and development of an AI+high-throughput digital biotechnology macromolecular…
-
Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations
•
Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has successfully completed a Series B+ financing round, raising RMB 100 million (USD 14 million). The round was led by Costone Asset Management, with significant contributions from Guanghua Holding, JYTH Investment, Lilly Asia ventures, and 3E…
-
Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million (USD 84 million) through a private placement of 38,969,401 shares, priced at RMB 15.36 per share. This strategic move aims to bolster the company’s financial position and support its expansion plans. Focus on Core Business…
-
United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology
•
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million (USD 6.3 million) to acquire a 4.7% stake in Shanghai Apactron Particle Equipment Co., Ltd., a company specializing in high-end particle therapy technology. This strategic deal is aimed at leveraging Apactron’s expertise in proton therapy…
-
AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa
•
US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), has taken legal action against BeiGene’s (NASDAQ: BGNE) BTK inhibitor Brukinsa (zanubrutinib). The lawsuit was filed by AbbVie subsidiary Pharmacyclics in the Delaware District Court on the day it was awarded a new…
-
VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities
•
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a stake in its Shanghai unit to entities backed by Singapore’s investment fund Temasek and China-based HighLight Capital, raising RMB 1.06 billion (USD 148.7 million). This transaction reduces VIVA Biotech’s stake in VIVA Shanghai from 100%…
